Hanmi Science (008930) - Total Liabilities
Based on the latest financial reports, Hanmi Science (008930) has total liabilities worth ₩494.84 Billion KRW (≈ $335.34 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hanmi Science - Total Liabilities Trend (2000–2025)
This chart illustrates how Hanmi Science's total liabilities have evolved over time, based on quarterly financial data. Explore Hanmi Science long-term investment allocation to see how much of total assets are deployed in long-term investments.
Hanmi Science Competitors by Total Liabilities
The table below lists competitors of Hanmi Science ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Crystal Clear Chemical Co Ltd
SHE:300655
|
China | CN¥1.45 Billion |
|
Cadeler As
OL:CADLR
|
Norway | Nkr1.61 Billion |
|
Also Holding AG
SW:ALSN
|
Switzerland | CHF3.96 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥2.72 Billion |
|
HUISHANG BK CORP. H YC1
F:HB8
|
Germany | €2.09 Trillion |
|
Sineng Electric Co Ltd
SHE:300827
|
China | CN¥6.67 Billion |
|
Tangshan Sanyou Chemical Industries Co Ltd
SHG:600409
|
China | CN¥11.24 Billion |
|
OPmobility SE
PA:OPM
|
France | €5.77 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Hanmi Science's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hanmi Science balance sheet assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hanmi Science's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hanmi Science (2000–2025)
The table below shows the annual total liabilities of Hanmi Science from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩529.85 Billion ≈ $359.07 Million |
+3.82% |
| 2024-12-31 | ₩510.38 Billion ≈ $345.87 Million |
+16.34% |
| 2023-12-31 | ₩438.70 Billion ≈ $297.30 Million |
+13.96% |
| 2022-12-31 | ₩384.94 Billion ≈ $260.87 Million |
+48.28% |
| 2021-12-31 | ₩259.60 Billion ≈ $175.93 Million |
-1.85% |
| 2020-12-31 | ₩264.49 Billion ≈ $179.24 Million |
-0.25% |
| 2019-12-31 | ₩265.15 Billion ≈ $179.69 Million |
+0.64% |
| 2018-12-31 | ₩263.45 Billion ≈ $178.54 Million |
-3.72% |
| 2017-12-31 | ₩273.63 Billion ≈ $185.44 Million |
-14.94% |
| 2016-12-31 | ₩321.68 Billion ≈ $218.00 Million |
-7.50% |
| 2015-12-31 | ₩347.77 Billion ≈ $235.68 Million |
+6.98% |
| 2014-12-31 | ₩325.08 Billion ≈ $220.30 Million |
+90.38% |
| 2013-12-31 | ₩170.76 Billion ≈ $115.72 Million |
+86.62% |
| 2012-12-31 | ₩91.50 Billion ≈ $62.01 Million |
+169.83% |
| 2011-12-31 | ₩33.91 Billion ≈ $22.98 Million |
-92.02% |
| 2010-12-31 | ₩424.95 Billion ≈ $287.98 Million |
-5.69% |
| 2009-12-31 | ₩450.57 Billion ≈ $305.34 Million |
+1.15% |
| 2008-12-31 | ₩445.43 Billion ≈ $301.86 Million |
+31.25% |
| 2007-12-31 | ₩339.39 Billion ≈ $230.00 Million |
+44.80% |
| 2006-12-31 | ₩234.39 Billion ≈ $158.84 Million |
+23.83% |
| 2005-12-31 | ₩189.29 Billion ≈ $128.28 Million |
+3.40% |
| 2004-12-31 | ₩183.07 Billion ≈ $124.06 Million |
+6.31% |
| 2003-12-31 | ₩172.20 Billion ≈ $116.70 Million |
+8.25% |
| 2002-12-31 | ₩159.07 Billion ≈ $107.80 Million |
-3.08% |
| 2001-12-31 | ₩164.13 Billion ≈ $111.23 Million |
+5.05% |
| 2000-12-31 | ₩156.24 Billion ≈ $105.88 Million |
-- |
About Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more